Skip to main content

Research Repository

Advanced Search

All Outputs (10)

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder (2021)
Journal Article
Challapalli, A., Masson, S., White, P., Dailami, N., Pearson, S., Rowe, E., …Bahl, A. (2021). A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder. Clinical Genitourinary Cancer, 19(4), P325-332. https://doi.org/10.1016/j.clgc.2021.02.001

Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal. We evaluated the efficacy, safety, and tolerability of cisplatin plus caba... Read More about A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.

Intramuscular oxytocin versus Syntometrine® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double-blinded clinical trial of effectiveness, side effects and quality of life (2020)
Journal Article
van der Nelson, H., O’Brien, S., Burnard, S., Mayer, M., Alvarez, M., Knowlden, J., …Draycott, T. (in press). Intramuscular oxytocin versus Syntometrine® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double-blinded clinical trial of effectiveness, side effects and quality of life. BJOG: An International Journal of Obstetrics and Gynaecology, 128(7), 1236-1246. https://doi.org/10.1111/1471-0528.16622

Objective: To compare intramuscular oxytocin, Syntometrine® and carbetocin for prevention of postpartum haemorrhage after vaginal birth. Design: Randomised double-blinded clinical trial. Setting: Six hospitals in England. Population: A total of 5929... Read More about Intramuscular oxytocin versus Syntometrine® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double-blinded clinical trial of effectiveness, side effects and quality of life.

Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder (2020)
Journal Article
Challapalli, A., Masson, S., White, P., Dailami, N., Pearson, S., Rowe, E., …Bahl, A. (2020). Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder. Journal of Clinical Oncology, 38(15 Suppl.), 5030-5030. https://doi.org/10.1200/JCO.2020.38.15_suppl.5030

Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns (2018)
Journal Article
Hollén, L., Hughes, R., Dodds, N., Coy, K., Marlow, K., Pullan, N., …Young, A. (2019). Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns. Trauma, 21(3), 192-200. https://doi.org/10.1177/1460408618760940

Introduction: Accurate and early detection of sepsis poses a significant challenge in burn populations. Our objective was to assess whether procalcitonin is a marker of blood culture positive sepsis in moderate to severe paediatric burns. Methods: We... Read More about Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns.

The Bristol Bladder trial: A single-arm phase II trial of cisplatin and cabazitaxel for muscle invasive transitional cell carcinoma of the urinary bladder prior to radical cystectomy (2018)
Journal Article
Bahl, A., Masson, S., Challapalli, A., Bravo, A., Pearson, S., Hilman, S., …Holly, J. (2018). The Bristol Bladder trial: A single-arm phase II trial of cisplatin and cabazitaxel for muscle invasive transitional cell carcinoma of the urinary bladder prior to radical cystectomy. Journal of Clinical Oncology, 36, 468-468. https://doi.org/10.1200/JCO.2018.36.6_suppl.468

The safety of general anaesthesia in paediatric patients undergoing the application of Biobrane® for small scalds (2015)
Journal Article
Young, A. E., Lobo, C. A., Warwicker, S. J., Warwicker, S., Lobo, C., Dailami, N., & Young, A. (2015). The safety of general anaesthesia in paediatric patients undergoing the application of Biobrane® for small scalds. Burns, 41(6), 1221-1226. https://doi.org/10.1016/j.burns.2015.02.007

© 2015 Elsevier Ltd and ISBI. All rights reserved. Background Each year more than 5000 children present to English and Welsh hospitals for the management of scalds; 60% of these are small scalds of less than 10% body surface area. There are no agreed... Read More about The safety of general anaesthesia in paediatric patients undergoing the application of Biobrane® for small scalds.

Food for life partnership evaluation: Full report (2011)
Report
Orme, J., Jones, M., Kimberlee, R., Weitkamp, E., Salmon, D., Dailami, N., …Morgan, K. (2011). Food for life partnership evaluation: Full report

Full report on the evaluation of the Food for Life Partnership programme. May 2011

Food for life partnership evaluation: summary report (2011)
Report
Orme, J., Jones, M., Kimberlee, R., Weitkamp, E., Salmon, D., Dailami, N., …Morgan, K. (2011). Food for life partnership evaluation: summary report

Summary report of the Food for Life Partnership evaluation conducted by UWE,Bristol and Cardiff University. May 2011

Selecting the best population: A decision theoretic approach: The case of Pareto distribution (1985)
Report
Dailami, N., Subramanyam, K., & Rao, M. B. (1985). Selecting the best population: A decision theoretic approach: The case of Pareto distribution

The main ideas in selecting the best populations meeting some prescribed optimality criterion have been mooted originally by Bechchofer and Gupta and the subject has gone from strength to strength by several contributions by several statisticians ove... Read More about Selecting the best population: A decision theoretic approach: The case of Pareto distribution.